Five Prime Therapeutics Stock News

Five Prime Therapeutics Reports First Quarter 2020 Results

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call

Bank of New York Mellon Corp cut its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 18.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi

Five Prime Therapeutics Inc (NASDAQ:FPRX) rose 6.3% during mid-day trading on Friday . The stock traded as high as $3.05 and last traded at $3.02, approximately 154,668 shares changed hands during tra

Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, has named Kyle Skiermont, PharmD, as senior vice president, specialty pharmacy and hom

Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format

Information on investments, active portfolio, exits, fund performance, dry powder, team and co-investors for Fred Cohen. Use the PitchBook Platform to explore the full profile.

Equities analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to announce ($0.68) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Five

Five Prime Therapeutics (NASDAQ:FPRX) and Innovus Pharmaceuticals (OTCMKTS:INNV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Five Prime Therapeutics Inc (NASDAQ:FPRX) was the recipient of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 1,270,000 shares, a decrease of 1

Cubist Systematic Strategies LLC increased its position in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 106.4% in the 4th quarter, according to the company in its most recent disclosure with the Secur